DIGITALIN
-
| StockNo |
Product description |
Status |
| EB0280-424-08 |
DIGITALIN
VIAL 10 ML 1 % SOLUTION |
 |
-
- COMPOSITION:
Digitoxin 1 % - 10 ml.
ACTION:
A preparation with a potent cardiotonic action. It is the most
active glucoside of Digitalis purpurea. Digitoxin enhances the
systole, prolongs the diastole and regulates the cardiac rhythm. It
restricts the blood vessels in the abdominal cavity, improving
coronary blood flow, eliminates the congestive phenomena in cases of
cardiac decompensation, and regulates the circulation. Digitalin is
the most toxic digitalis preparation, owing to its considerable
content of digitoxin.
PHARMACOKINETICS:
Its action begins 30 min after administration, the maximum effect
comes after 4-12 h. the preparation is eliminated through the liver
and is characterized by a small therapeutic range and symptoms of
cumulation. The preparation is quickly and almost fully absorbed by
the gastrointestinal tract. Its absorption is facilitated if the
preparation is taken with food rich in fats.
INDICATIONS:
Chronic cardiac insufficiency of II and III degree with different
origin - mitral valvular disease, hypertension, myocardial
dystrophy, myocardial sclerosis and tachyarythmic form of atrial
flutter and fibrillation.
CONTRAINDICATIONS:
Absolute contraindications - venticular tachycardia ( it may turn
into venticular flutter) and digitalin intoxication. The application
of the preparation is not advisable in cases of pronounced
bradycardia (under 50 beats per min), conduction disturbances and
full atrioventicular block, heavy stenocardia, insult, pulmonary
embolism and renal insufficiency.
SIDE EFFECTS:
Anorexia, nausea, vomiting, hemorrhagic lesions of the gastric and
duodenal mucosa, diarrhea, slight disturbances, bradycardia,
polytopic extrasystoles, AV-block, coronary nspasm, reduced diuresis,
headache, aphasia, hallucination, gynecomastia and eruptions. |
PRECAUTIONS:
At appearance of toxic symptoms during the treatment, the
administration of digitalin is discontinued, and atropine and
potassium preparations are administered. The transition from
digitalis therapy to treatment with another cardiac glycoside must
be made several days after digitalin has been stopped, and under ECG-control.
DRUG INTERACTIONS:
The action of digitalin increases under the influence of diuretics,
calcium and magnesium preparations, reserpin, sympathomimetics and
parasympathicolytics. Probenecid and etacrinic acid inhibit the
resorption of digitoxin in the small intestine. It is not advisable
to combine the preparation withtolbutamide and clofibrate, which are
bound to the plasma albumins and thus increase the elimination of
digitoxin from the organism, which makes the choice of adequate
doses difficult.
DOSAGE AND ADMINISTRATION:
Digitalin is applied orally. It is dosed individually, depending on
the nature and the degree of insufficiency. For slow digitalization
digitalin is applied in doses of 5 drops before the meals, 3 times
daily for 4-6 days. In higher cases 75-90 drops are usually enough
for a treatment course, in more severe cases - up to 100 drops. The
full saturating dose of digitalin is 1.5 to 2 mg. The supporting
dose is from 0.1 to 0.2 mg daily, this dose being applied during a
long period with pauses of 2-5 days.
MEDICINAL FORM AND PACKAGE:
1 % solution in vials of 10 ml.
STORAGE:
At moderate temperature (15-30° C) in a place protected from direct
sunlight.
EXPIRY:
1 (one) year.
|
